NCT02746952CompletedPhase 1
Phase I, Open Label, Dose-escalation Study Followed by a Safety Expansion Part to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL)
Institut de Recherches Internationales Servier9 sites in 4 countries25 target enrollmentStarted: August 1, 2016Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 25
- Locations
- 9
- Primary Endpoint
- Dose escalation part: Dose Limiting Toxicities (DLTs) occurence. Dose expansion part: AE throughout the study.
Study Overview
Brief Summary
The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single infusion in patients with relapsed / refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), to determine the maximum tolerated dose (MTD), the recommended dose and the lymphodepletion regimen. The purpose of the safety dose expansion is to assess the safety and tolerability of the RD for UCART19.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 16 Years to 69 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female participant
- •Age ≥ 16 years
- •Patient with relapsed or refractory CD19 positive B-acute lymphoblastic leukaemia (B-ALL) who have exhausted alternative treatment options
- •Estimated life expectancy ≥ 12 weeks (according to investigator's judgement)
- •Eastern Cooperative Oncology Group (ECOG) performance status < 2
Exclusion Criteria
- •Previous treatment with gene or gene-modified cell therapy medicine products or adoptive T cell therapy
- •Use of previous anti-leukemic therapy (including approved therapies and other investigational products) within 5 half-lives prior to UCART19 administration
- •CD19 negative B-cell leukaemia
- •Burkitt cell or mixed lineage acute leukaemia
Arms & Interventions
UCART19
Experimental
Intervention: UCART19 (Biological)
Outcomes
Primary Outcomes
Dose escalation part: Dose Limiting Toxicities (DLTs) occurence. Dose expansion part: AE throughout the study.
Time Frame: Dose Escalation: Up to day 28 post first UCART19 infusion. Dose Expansion: From inclusion to Month 12
Secondary Outcomes
- Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability(From inclusion to Month 12)
- Duration of remission(From the time that response criteria are first met until the date of progression or death (whatever the reason of death), whichever occurs first, assessed up to Month 12)
- Overall Survival (OS)(From the date of UCART19 administration to the date of death from any cause, assessed up to Month 12)
- Objective Remission Rate(At Day 28, Day 84, Month 4, Month 6, Month 9 and Month12)
- Progression Free Survival (PFS)(From the date of UCART19 administration until the date of progression or the date of death (whatever the reason of death), whichever occur first, assessed up to Month 12)
- Time to remission(From the date of UCART19 administration until the date that response criteria are met, assessed up to Month 12)
Investigators
Study Sites (9)
Loading locations...
Similar Trials
Completed
Phase 1
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)NeoplasmsNCT03918278Merck Sharp & Dohme LLC222
Recruiting
Phase 1
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid TumorsNCT06752681Day One Biopharmaceuticals, Inc.300
Completed
Phase 1
Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid TumorsSolid TumorNCT05547906MetaFines18
Recruiting
Phase 1
A Phase 1 Study of LNCB74 in Advanced Solid TumorsOvarian CancerAdvanced or Metastatic Solid TumorsNon-Small Cell Lung CancerBreast CancerEndometrial CancerBiliary Tract CancerNCT06774963NextCure, Inc.145
Completed
Phase 1
NUC-3373 in Advanced Solid TumoursCancerNCT02723240University of Oxford62